Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 15/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 11/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.59 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.57 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine 5'-Phosphate SCHEMBL16516255 | 0.94 | P2RY2 (0.56) | P2RY2P2RY6P2RY4 | |
| Cytarabine 5'-Phosphate SCHEMBL29359440 | 0.89 | P2RY2 (0.70) | P2RY2P2RY6P2RY4RNASEL | |
| Cytarabine 5'-Phosphate SCHEMBL19347100 | 0.88 | P2RY2 (0.85) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL184241 | 0.83 | P2RX3 (0.61) | P2RY2 | |
| SCHEMBL2683124 | 0.83 | P2RX3 (0.61) | P2RY2 | |
| Cytarabine 5'-Phosphate SCHEMBL29424346 | 0.82 | P2RX3 (0.69) | P2RY2 | |
| Cytarabine 5'-Phosphate SCHEMBL29356502 | 0.82 | P2RX3 (0.69) | P2RY2 | |
| Uridine Triphosphate SCHEMBL25298912 | 0.82 | P2RY2 (0.92) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL15082664 | 0.80 | P2RY2 (1.00) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL25248334 | 0.80 | P2RY2 (0.80) | P2RY2P2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8352 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12595280-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2026-04-07 | — | — | US | claimed |
| EP-3534910-B1 | RIFAMPICIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | POP TEST ONCOLOGY LLC (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260060964-A1 | METHODS AND COMPOSITIONS FOR TREATING SEPSIS | ANTIVIRUS THERAPEUTICS (US) | 2026-03-05 | — | — | US | claimed |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2026-02-12 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4673568-A1 | MICROBIAL BIOMARKERS IN TRANSPLANTATION AND RELATED METHODS | Karius, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2025264805-A2 | SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2002085358-A2 | ANTIVIRAL AGENTS AND METHODS OF TREATING VIRAL INFECTIONS | VION PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | claimed |
| CN-1302612-A | Process for preparing pharmaceutical composition containing 1, 3-oxathiolane nucleoside analogue | IAF BIOCHEM INT (CA) | 2001-07-11 | — | — | CN | claimed |
| EP-1098641-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | Texas Pharmaceuticals, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6180639-B1 | THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-01-30 | — | — | US | claimed |
| EP-1062950-A2 | 1,3 Oxathiolane nucleoside analogues | BIOCHEM PHARMA INC (CA) | 2000-12-27 | — | — | EP | claimed |
| CN-1057231-C | Modulation of AIDS virus-related events by double-stuanded RNAs | HEM RES INC (US) | 2000-10-11 | — | — | CN | claimed |
| WO-2000006143-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. (US) | 2000-02-10 | — | — | WO | claimed |
| US-5357636-A | Flexible protective medical gloves and methods for their use | DRESDNER JR KARL P (US) | 1994-10-25 | — | — | US | claimed |
| US-4900548-A | AIDS TREATMENT | HARVARD UNIVERSITY (US) | 1990-02-13 | — | — | US | claimed |
| EP-0286224-A2 | Treatment of human viral infection by dsRNA combined with viral inhibitors | HEM PHARMACEUTICALS CORP. (US) | 1988-10-12 | — | — | EP | claimed |